Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025

Phathom Pharmaceuticals, Inc.

Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.
Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.
Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.
Board determined Schroeder meets Nasdaq independence standards; no related party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Theodore R. Schroeder

Director

PHAT · Phathom Pharmaceuticals, Inc.

Effective: 2025-04-16
Filed: April 16, 2025, 7:59 PM ET

The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Theodore R. Schroeder was appointed as Director at Phathom Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025

View on SEC.gov

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-082089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.